Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Schwartz

Showing results (181-190 of 204) with videos related to

Pageof 21
Sort By:
Journal of Hematology & Oncology|January 30, 2020
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemiaOla A Elgamal, Abeera Mehmood, Jae Yoon Jeon, et al.
Oncotarget|January 26, 2017
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinomaNicola Personeni, Laura Giordano, Giovanni Abbadessa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung CancerGiorgio Scagliotti, Joachim von Pawel, Silvia Novello, et al.
The New England Journal of Medicine|January 12, 2007
Sorafenib in advanced clear-cell renal-cell carcinomaBernard Escudier, Tim Eisen, Walter M Stadler, et al.
Cancer Discovery|November 6, 2023
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin LymphomaJennifer A Woyach, Deborah M Stephens, Ian W Flinn, et al.
American Journal of Human Genetics|February 27, 2019
Pharmacodynamic Study of Miransertib in Individuals with Proteus SyndromeKim M Keppler-Noreuil, Julie C Sapp, Marjorie J Lindhurst, et al.
British Journal of Cancer|November 14, 2018
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinomaVincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, et al.
Journal of Medicinal Chemistry|June 16, 2016
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT InhibitorJean-Marc Lapierre, Sudharshan Eathiraj, David Vensel, et al.
British Journal of Cancer|October 16, 2018
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosisDavid E Gerber, M Shaalan Beg, Farjana Fattah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesTimothy A Yap, David Olmos, Andre T Brunetto, et al.
Pageof 21

Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
Journal of Hematology & Oncology|January 30, 2020
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemiaOla A Elgamal, Abeera Mehmood, Jae Yoon Jeon, et al.
Oncotarget|January 26, 2017
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinomaNicola Personeni, Laura Giordano, Giovanni Abbadessa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung CancerGiorgio Scagliotti, Joachim von Pawel, Silvia Novello, et al.
The New England Journal of Medicine|January 12, 2007
Sorafenib in advanced clear-cell renal-cell carcinomaBernard Escudier, Tim Eisen, Walter M Stadler, et al.
Cancer Discovery|November 6, 2023
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin LymphomaJennifer A Woyach, Deborah M Stephens, Ian W Flinn, et al.
American Journal of Human Genetics|February 27, 2019
Pharmacodynamic Study of Miransertib in Individuals with Proteus SyndromeKim M Keppler-Noreuil, Julie C Sapp, Marjorie J Lindhurst, et al.
British Journal of Cancer|November 14, 2018
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinomaVincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, et al.
Journal of Medicinal Chemistry|June 16, 2016
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT InhibitorJean-Marc Lapierre, Sudharshan Eathiraj, David Vensel, et al.
British Journal of Cancer|October 16, 2018
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosisDavid E Gerber, M Shaalan Beg, Farjana Fattah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesTimothy A Yap, David Olmos, Andre T Brunetto, et al.
Pageof 21